Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

New on Charts:

We've added Splits, Dividends, Earnings, and Earnings Estimates! Click on individual events to unveil more details.

If you prefer a cleaner view, easily disable them in Settings.

VERU | Veru Inc

Index- P/E- EPS (ttm)-1.38 Insider Own23.20% Shs Outstand80.51M Perf Week-17.06%
Market Cap64.91M Forward P/E- EPS next Y-0.59 Insider Trans0.00% Shs Float69.33M Perf Month-34.64%
Income-110.34M PEG- EPS next Q-0.23 Inst Own17.21% Short Float / Ratio17.03% / 12.56 Perf Quarter-39.58%
Sales15.02M P/S4.32 EPS this Y-1.43% Inst Trans-9.72% Short Interest11.81M Perf Half Y-40.08%
Book/sh0.39 P/B1.87 EPS next Y44.60% ROA-93.60% Target Price4.50 Perf Year-93.53%
Cash/sh0.18 P/C4.00 EPS next 5Y- ROE-145.90% 52W Range0.72 - 15.90 Perf YTD-86.38%
Dividend- P/FCF- EPS past 5Y-33.30% ROI-232.45% 52W High-95.48% Beta-0.01
Dividend %- Quick Ratio1.33 Sales past 5Y31.73% Gross Margin42.99% 52W Low-0.14% ATR0.07
Employees233 Current Ratio1.56 Sales Q/Q-65.20% Oper. Margin-854.50% RSI (14)27.24 Volatility10.40% 7.70%
OptionableYes Debt/Eq0.44 EPS Q/Q- Profit Margin-734.47% Rel Volume1.21 Prev Close0.75
ShortableYes LT Debt/Eq0.38 EarningsAug 10 BMO Payout- Avg Volume940.14K Price0.72
Recom1.00 SMA20-24.68% SMA50-32.39% SMA200-68.93% Volume1,138,069 Change-4.44%
Date Action Analyst Rating Change Price Target Change
Jun-07-23Upgrade Jefferies Underperform → Hold $1
Apr-13-21Initiated Jefferies Buy $19
Feb-09-21Reiterated H.C. Wainwright Buy $12 → $17
Jan-21-20Reiterated H.C. Wainwright Buy $4.50 → $6
Mar-20-19Initiated Oppenheimer Outperform $5
Jul-03-18Initiated Maxim Group Buy
Sep-26-23 08:30AM
Sep-20-23 08:30AM
Sep-11-23 07:00AM
Aug-30-23 08:30AM
Aug-11-23 08:15AM
07:50AM Loading…
Aug-10-23 07:50AM
Aug-03-23 08:30AM
Jun-21-23 08:30AM
Jun-01-23 08:30AM
May-24-23 08:30AM
May-11-23 08:09AM
May-09-23 11:15AM
10:00AM Loading…
May-04-23 10:00AM
May-03-23 08:30AM
Apr-27-23 06:45AM
Apr-20-23 06:45AM
Apr-19-23 08:30AM
Apr-12-23 09:35AM
Apr-11-23 03:49PM
Apr-04-23 08:30AM
Mar-27-23 06:37AM
Mar-14-23 01:36PM
Mar-07-23 08:30AM
Mar-03-23 11:27AM
04:01PM Loading…
Mar-02-23 04:01PM
Feb-14-23 06:06AM
Feb-10-23 03:11PM
Feb-09-23 07:45AM
Jan-26-23 08:30AM
Jan-17-23 05:32AM
Jan-10-23 08:30AM
Dec-29-22 05:57AM
Dec-10-22 09:45AM
Dec-08-22 01:59PM
Dec-07-22 08:15AM
Dec-05-22 08:00AM
Dec-02-22 09:00AM
Nov-28-22 08:30AM
Nov-23-22 05:54PM
Nov-22-22 09:15AM
Nov-21-22 06:10PM
Nov-13-22 07:46AM
Nov-11-22 03:15PM
Nov-10-22 04:11PM
Nov-09-22 08:55PM
Nov-08-22 02:56AM
Nov-07-22 04:15PM
Oct-24-22 08:30AM
Oct-13-22 08:30AM
Oct-09-22 09:45AM
Oct-04-22 04:30PM
Sep-26-22 06:45AM
Sep-23-22 07:51AM
Sep-21-22 08:30AM
Sep-19-22 12:15PM
Sep-08-22 07:14AM
Sep-07-22 01:45PM
Sep-06-22 08:30AM
Sep-02-22 10:37AM
Aug-30-22 01:33PM
Aug-28-22 03:07PM
Aug-25-22 10:15AM
Aug-22-22 08:30AM
Aug-19-22 08:30AM
Aug-16-22 10:15AM
Aug-15-22 09:15AM
Aug-13-22 08:07AM
Aug-12-22 04:30PM
Aug-11-22 12:48PM
Aug-10-22 10:45AM
Aug-09-22 08:30AM
Aug-03-22 07:45PM
Jul-31-22 09:35AM
Jul-29-22 06:15PM
Jul-28-22 08:30AM
Jul-27-22 11:00AM
Jul-25-22 07:30AM
Jul-14-22 12:13PM
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm's breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company's sexual health business' commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.